BIO-TECHNOLOGY GENERAL CORP. ANNOUNCES YEAR-END 1995 RESULTS; First Profitable Year, Income of $4.8 Million in 1995 vs. Loss of $7.4 Million in 1994.

ISELIN, N.J.--(BUSINESS WIRE)--April 1, 1996--Bio-Technology General Corp. (NASDAQ:BTGC) today announced its financial results for 1995, its first profitable year. Net income for 1995 was $4.8 million, or $0.11 per share on revenue of $28.0 million, compared to a 1994 net loss of $7.4 million, or $0.19 per share on revenue of $17.4 million.

Net income for 1995 and 1994 reflect an extraordinary gain of $1.4 million, or $0.03 per share and $1.5 million, or $0.04 per share, respectively, due to debt forgiveness, as well as, in 1995, research and development revenue of approximately $3.0 million resulting from the return of warrants in connection with the wind-up of the Company's relationship with Bio-Cardia Corporation. Cash, cash equivalents and short-term investments at December 31 were $10.9 million in 1995 as compared to $16.9 million in 1994.

Revenues from product sales rose 95% in 1995 to $21.4 million as compared to $11.0 million in 1994. The increase in product sales in 1995 reflects broader worldwide distribution of the Company's human growth hormone and hyaluronic acid and the U.S. launch of Oxandrin. in December 1995. Expenses declined 7% from $26.4 million in 1994 to $24.5 million in 1995.

Sim Fass, president and chief executive officer of Bio-Technology General Corp., stated: "In achieving profitability in 1995 for the first time, we have joined the very few first tier biotech companies that have become profitable. This is an achievement of which we are justifiably proud. In 1995 total revenues were up approximately 60% compared to 1994 and product sales nearly doubled. Moreover, we expect to report further growth in sales and net income in 1996, as our products gain wider distribution and penetration worldwide."

Bio-Technology General Corp. develops, manufactures and markets genetically engineered and other products for human health care. -0-

            BIO-TECHNOLOGY GENERAL CORP. AND SUBSIDIARIES
                 CONSOLIDATED STATEMENTS OF OPERATIONS
                  (in thousands except per share data)

                                    Year Ended December 31,
                                      1995           1994

Revenues:
  Product sales                     $   21,428   $   11,047
  Contract fees                            591          762
  Research and development revenues
   under collaborative agreements        4,041        3,652
  Other revenues                         1,113        1,476
  Interest income                          787          503

          Total revenues                27,960       17,440

Expenses:
  Research and development              10,935       13,714
  Cost of product sales                  3,913        2,168
  General and administrative             8,005        9,743
  Commissions and royalties                726          444
  Interest and finance                     159          290
  Research and development financing       806           --

          Total expenses                24,544       26,359

Income (loss) before extraordinary
 gain                                    3,416       (8,919)
Extraordinary gain                       1,363        1,500
Net income (loss)                    $   4,779   $   (7,419)

Earnings (loss) per common share:

Income (loss) per common share
  before extraordinary gain          $   0.08    $   (0.23)
Extraordinary gain per common share      0.03         0.04
Net income (loss) per common share   $   0.11    $   (0.19)

Weighted average number of common
  and common equivalent shares         43,784       38,725

CONTACT: Bio-Technology General Corp., Iselin

Leah Berkovits, 908-632-8800

or

Investor Relations

Strategic Growth International

Don Weinberger, 516-829-7111